Dichloro‐[1‐(hydroxyphenyl)‐2‐phenylethylenediamine]platinum(II) Complexes: Testing on the Human Ovarian Cancer Cell Lines NIH: OVCAR 3 and SK OV 3 | Zendy

Bernhardt Günther | Zendy; Müller Richard | Zendy; Gust Ronald | Zendy; Reile Herta | Zendy; Keller Christoph | Zendy; Spruß Thilo | Zendy; Schönenberger Helmut | Zendy

Premium

Dichloro‐[1‐(hydroxyphenyl)‐2‐phenylethylenediamine]platinum(II) Complexes: Testing on the Human Ovarian Cancer Cell Lines NIH: OVCAR 3 and SK OV 3

Author(s) -

Bernhardt Günther,

Müller Richard,

Gust Ronald,

Reile Herta,

Keller Christoph,

Spruß Thilo,

Schönenberger Helmut

Publication year - 1992

Publication title -

archiv der pharmazie

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.468

H-Index - 61

eISSN - 1521-4184

pISSN - 0365-6233

DOI - 10.1002/ardp.19923250208

Subject(s) - ethylenediamine , cisplatin , chemistry , cell culture , platinum , ovarian cancer , stereochemistry , cancer research , cancer , biochemistry , medicine , chemotherapy , biology , organic chemistry , genetics , catalysis

The diastereoisomeric dichloro‐[1‐(2‐, 3‐ and 4‐hydroxyphenyl)‐2‐phenyl‐ethylenediamine]platinum(II) complexes were tested on two human ovarian cancer cell lines NIH: OVCAR‐3 and SK‐OV‐3, both resistant against cisplatin. Dichloro‐[ threo ‐1‐(3‐hydroxyphenyl)‐2‐phenylethylenediamine]platinum(II) ( threo ‐ 5 ‐PtCl 2 ) proved to be the most active representative of the new series, producing cytocidal effects at a concentration range of 2. 5 to 5. 0 μM on the NIH: OVCAR‐3 cell line. On the more resistant SK‐OV‐3 cell line, threo ‐ 5 ‐PtCl 2 was only moderately active, while in combination with BSO, a GSH level lowering compound, threo ‐ 5 ‐PtCl 2 showed a strong synergistic effect.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research